Spinal Cord Diseases
Pathologic conditions which feature SPINAL CORD damage or dysfunction, including disorders involving the meninges and perimeningeal spaces surrounding the spinal cord. Traumatic injuries, vascular diseases, infections, and inflammatory/autoimmune processes may affect the spinal cord.
Subtype terms (13)
More specific conditions that are subtypes of Spinal Cord Diseases in the MeSH hierarchy.
- Amyotrophic Lateral Sclerosis
291 drugs (123 approved, 168 experimental)
- Muscular Atrophy, Spinal
32 drugs (19 approved, 13 experimental)
- Myelitis
5 drugs (4 approved, 1 experimental)
- Pneumorrhachis
- Spinal Cord Compression
6 drugs (4 approved, 2 experimental)
- Spinal Cord Injuries
211 drugs (108 approved, 103 experimental)
- Spinal Cord Neoplasms
17 drugs (11 approved, 6 experimental)
- Spinal Cord Vascular Diseases
- Spinocerebellar Degenerations
5 drugs (2 approved, 3 experimental)
- Stiff-Person Syndrome
18 drugs (15 approved, 3 experimental)
- Subacute Combined Degeneration
- Syringomyelia
3 drugs approved
- Tabes Dorsalis
Drugs by status
Approved for this indication (3)
Phase 4 trials (3)
Phase 3 trials (6)
Phase 2 trials (9)
Phase 1 trials (2)
Other trials (3)
Organizations
Organization Involved with Phase 4 Indications (8)
Organization Involved with Phase 3 Indications (18)
- Kyowa Hakko Kirin
- Mundipharma
- Medical Research Council
- National Institute of Neurological Disorders and Stroke (NINDS)
- National Institute on Drug Abuse (NIDA)
- University of London
- University of Washington
- Seoul National University
- St. Marianna University School of Medicine
- University of Michigan
- University of Toronto
- University of Birmingham
- University of California, Davis
- University of California, San Diego
- University of Cambridge
- Rush University
- Department of Veteran Affairs
- AO Foundation
Organization Involved with Phase 2 Indications (9)
Organization Involved with Phase 1 Indications (2)
Organization Involved with Other Experimental Indications (4)